Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib and Paclitaxel in Refractory Solid Tumors
NCT02379416Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2015
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nilotinib in solid tumor, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at Cycle 1 and Safety and Tolerability at Cycle 1. Started Apr 2015; status: completed.
02
Drugs
nilotinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02379416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02379416.